BACKGROUND: The long-term efficacy and safety of aclidinium bromide, a novel, long-acting muscarinic antagonist, were investigated in patients with moderate to severe chronic obstructive pulmonary disease (COPD). METHODS: In two double-blind, 52-week studies, ACCLAIM/COPD I (n=843) and II (n=804), patients were randomised to inhaled aclidinium 200 μg or placebo once-daily. Patients were required to have a post-bronchodilator forced expiratory volume in 1 second (FEV1)/forced vital capacity ratio of ≤70% and FEV1<80% of the predicted value. The primary endpoint was trough FEV1 at 12 and 28 weeks. Secondary endpoints were health status measured by St George's Respiratory Questionnaire (SGRQ) and time to first moderate or severe COPD exacerbation. RESULTS: At 12 and 28 weeks, aclidinium improved trough FEV1 versus placebo in ACCLAIM/COPD I (by 61 and 67 mL; both p<0.001) and ACCLAIM/COPD II (by 63 and 59 mL; both p<0.001). More patients had a SGRQ improvement≥4 units at 52 weeks with aclidinium versus placebo in ACCLAIM/COPD I (48.1% versus 39.5%; p=0.025) and ACCLAIM/COPD II (39.0% versus 32.8%; p=0.074). The time to first exacerbation was significantly delayed by aclidinium in ACCLAIM/COPD II (hazard ratio [HR] 0.7; 95% confidence interval [CI] 0.55 to 0.92; p=0.01), but not ACCLAIM/COPD I (HR 1.0; 95% CI 0.72 to 1.33; p=0.9). Adverse events were minor in both studies. CONCLUSION: Aclidinium is effective and well tolerated in patients with moderate to severe COPD. TRIAL REGISTRATION: ClinicalTrials.gov: NCT00363896 (ACCLAIM/COPD I) and NCT00358436 (ACCLAIM/COPD II).

Efficacy and safety of once-daily aclidinium in chronic obstructive pulmonary disease / Jones, Pw; Rennard, Si; Agusti, A; Chanez, P; Magnussen, H; Fabbri, Leonardo; Donohue, Jf; Bateman, Ed; Gross, Nj; Lamarca, R; Caracta, C; Gil, Eg. - In: RESPIRATORY RESEARCH. - ISSN 1465-9921. - STAMPA. - 12:(2011), pp. 55-65. [10.1186/1465-9921-12-55]

Efficacy and safety of once-daily aclidinium in chronic obstructive pulmonary disease.

FABBRI, Leonardo;
2011

Abstract

BACKGROUND: The long-term efficacy and safety of aclidinium bromide, a novel, long-acting muscarinic antagonist, were investigated in patients with moderate to severe chronic obstructive pulmonary disease (COPD). METHODS: In two double-blind, 52-week studies, ACCLAIM/COPD I (n=843) and II (n=804), patients were randomised to inhaled aclidinium 200 μg or placebo once-daily. Patients were required to have a post-bronchodilator forced expiratory volume in 1 second (FEV1)/forced vital capacity ratio of ≤70% and FEV1<80% of the predicted value. The primary endpoint was trough FEV1 at 12 and 28 weeks. Secondary endpoints were health status measured by St George's Respiratory Questionnaire (SGRQ) and time to first moderate or severe COPD exacerbation. RESULTS: At 12 and 28 weeks, aclidinium improved trough FEV1 versus placebo in ACCLAIM/COPD I (by 61 and 67 mL; both p<0.001) and ACCLAIM/COPD II (by 63 and 59 mL; both p<0.001). More patients had a SGRQ improvement≥4 units at 52 weeks with aclidinium versus placebo in ACCLAIM/COPD I (48.1% versus 39.5%; p=0.025) and ACCLAIM/COPD II (39.0% versus 32.8%; p=0.074). The time to first exacerbation was significantly delayed by aclidinium in ACCLAIM/COPD II (hazard ratio [HR] 0.7; 95% confidence interval [CI] 0.55 to 0.92; p=0.01), but not ACCLAIM/COPD I (HR 1.0; 95% CI 0.72 to 1.33; p=0.9). Adverse events were minor in both studies. CONCLUSION: Aclidinium is effective and well tolerated in patients with moderate to severe COPD. TRIAL REGISTRATION: ClinicalTrials.gov: NCT00363896 (ACCLAIM/COPD I) and NCT00358436 (ACCLAIM/COPD II).
2011
12
55
65
Efficacy and safety of once-daily aclidinium in chronic obstructive pulmonary disease / Jones, Pw; Rennard, Si; Agusti, A; Chanez, P; Magnussen, H; Fabbri, Leonardo; Donohue, Jf; Bateman, Ed; Gross, Nj; Lamarca, R; Caracta, C; Gil, Eg. - In: RESPIRATORY RESEARCH. - ISSN 1465-9921. - STAMPA. - 12:(2011), pp. 55-65. [10.1186/1465-9921-12-55]
Jones, Pw; Rennard, Si; Agusti, A; Chanez, P; Magnussen, H; Fabbri, Leonardo; Donohue, Jf; Bateman, Ed; Gross, Nj; Lamarca, R; Caracta, C; Gil, Eg...espandi
File in questo prodotto:
File Dimensione Formato  
1465-9921-12-55.pdf

Open access

Tipologia: Versione pubblicata dall'editore
Dimensione 540.58 kB
Formato Adobe PDF
540.58 kB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11380/806519
Citazioni
  • ???jsp.display-item.citation.pmc??? 27
  • Scopus 84
  • ???jsp.display-item.citation.isi??? 69
social impact